A5062746651- Ocular Oncology and Treatments
- Cancer-related Molecular Pathways
- Corneal Surgery and Treatments
- Retinal Development and Disorders
- Cutaneous Melanoma Detection and Management
- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Nonmelanoma Skin Cancer Studies
- CNS Lymphoma Diagnosis and Treatment
- Glaucoma and retinal disorders
- Cancer, Hypoxia, and Metabolism
- Head and Neck Surgical Oncology
- Cancer Immunotherapy and Biomarkers
- Ocular Infections and Treatments
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Drug-Induced Ocular Toxicity
- Nanoplatforms for cancer theranostics
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- interferon and immune responses
- Retinoids in leukemia and cellular processes
- Ocular Diseases and Behçet’s Syndrome
- melanin and skin pigmentation
- Cancer Genomics and Diagnostics
The University of Texas MD Anderson Cancer Center
2016-2025
The University of Texas Health Science Center at Houston
2024
Museum of Fine Arts, Houston
2016-2023
Baylor College of Medicine
2012-2023
The University of Texas Medical Branch at Galveston
2021-2023
Methodist Hospital
2021
Children's Cancer Center
2012-2020
Houston Methodist
2012-2019
Methodist Hospital
2012-2019
Texas Children's Hospital
2013-2018
Metastatic uveal melanoma has poor overall survival (OS) and no approved systemic therapy options. Studies of single-agent immunotherapy regimens have shown minimal benefit. There is the potential for improved responses with use combination immunotherapy.We conducted a phase II study nivolumab ipilimumab in patients metastatic melanoma. Any number prior treatments was permitted. Patients received 1 mg/kg 3 four cycles, followed by maintenance up to 2 years. The primary outcome response rate...
PurposeTo provide a set of surveillance guidelines for children at risk development retinoblastoma.DesignConsensus panel.ParticipantsExpert panel ophthalmic oncologists, pathologists, and geneticists.MethodsA group members the American Association Ophthalmic Oncologists Pathologists (AAOOP) with support Pediatric Ophthalmology Strabismus Academy Pediatrics (AAP) was convened. The included representative geneticists from retinoblastoma referral centers located in various geographic regions...
PURPOSEValidated and accurate prognostic testing is critical for precision medicine in uveal melanoma (UM). Our aims were to (1) prospectively validate an integrated classifier combining a 15-gene expression profile (15-GEP)
Aims: To evaluate how tumour size, retinal location, and patient age affect the outcome of retinoblastoma foci treated with chemotherapy. Methods: Retrospective review primary chemotherapy alone. Individual tumours were coded regard to their largest basal diameter, location within eye (macula, macula equator, equator ora serrata), patient9s at diagnosis. Successfully required no further intervention while those requiring additional treatment as failures. Results: 56 (72%) responded...
To date, no systemic therapy, including immunotherapy, exists to improve clinical outcomes in metastatic uveal melanoma (UM) patients. understand the role of immune infiltrates genesis, metastasis, and response treatment for UM, we systematically characterized profiles UM primary tumors, as well samples from patients treated with immunotherapies. Relevant markers (CD3, CD8, FoxP3, CD68, PD-1, PD-L1) were analyzed by immunohistochemistry on 27 31 tumors 47 UM. Immune gene expression profiling...
Metallic fiducial markers are frequently implanted in patients prior to external-beam radiation therapy facilitate tumor localization. There is little information the literature, however, about perturbations proton absorbed-dose distribution these objects cause. The aim of this study was assess dosimetric impact caused by 2.5 mm diameter 0.2 thick tantalum when used for treating uveal melanoma. Absorbed dose were measured using radiochromic film and confirmed Monte Carlo simulations...
Ocular toxicities are among the most common adverse events resulting from targeted anticancer agents and becoming increasingly relevant in management of patients on these agents. The purpose this study is to provide a framework for challenging based objective data FDA labels analysis literature. All oncologic drugs approved by up March 14, 2015, were screened inclusion. A total 16 (12 small-molecule 4 monoclonal antibodies) analyzed ocular toxicity profiles evidence toxicity. Trials cited...
The low response rates to immunotherapy in uveal melanoma (UM) sharply contrast with reputable cutaneous (CM) patients. To characterize the mechanisms responsible for resistance UM, we performed immune profiling tumors from 10 metastatic UM patients and CM by immunohistochemistry (IHC). Although there is no difference infiltrating CD8+ T cells between CM, a significant decrease programmed death-1 (PD-1)-positive lymphocytes was observed lower levels of death ligand-1 (PD-L1) metastases...
Nearly 50% of uveal melanoma (UM) patients develop metastatic disease, and there remains no current standard assay for detection minimal residual disease. We conducted a pilot study to check the feasibility circulating tumor cell (CTC) in UM. enrolled 40 with early or UM which 20 had early-stage 19 one was not evaluable. At initial blood draw, 36% detectable CTCs (30% vs. 42% metastatic), increased 54% at data cutoff (40% 68% metastatic). Five developed distant metastases, 60% (3/5) before...
In this study, we address one of the major critiques for tumor-infiltrating lymphocyte (TIL) therapy-the time needed proper expansion a suitable product. We postulated that T-cell receptor activation in first phase combined with an agonistic stimulation CD137/4-1BB and interleukin-2 would favor preferential CD8 TIL. Indeed, novel 3-signal approach optimal resulted faster more consistent CD8CD3 This new method allowed successful TIL from cutaneous uveal melanoma tumors 100% cultures <3 weeks....
The treatment of uveal melanoma with proton radiotherapy has provided excellent clinical outcomes. However, contemporary planning systems use simplistic dose algorithms that limit the accuracy relative distributions. Further, absolute predictions absorbed per monitor unit are not yet available in these systems. purpose this study was to determine if Monte Carlo methods could predict (D/MU) value at center a spread-out Bragg peak (SOBP) within 1% on measured values for variety fields relevant...
Uveal melanoma is an aggressive disease without effective adjuvant therapy for metastases. Despite genomic differences between cutaneous and uveal melanomas, therapies based on shared biological factors could be against both tumor types. High expression of glycoprotein-NMB (GPNMB) in melanomas led to the development CDX-011 (glembatumumab vedotin), a fully human monoclonal antibody extracellular domain GPNMB conjugated cytotoxic microtubule toxin monomethylauristatin E. Ongoing phase II...
Dear Editor,SARS-CoV-2, the virus that causes COVID-19, is a novel pathogen. It spreading rapidly in USA, and our understanding of its behavior, transmissibility, best practices to reduce risk for spread remain limited. Rationing resources already occurring response COVID-19 pandemic. The purpose this document lay basic framework ocular oncology care during current However, it important recognize complexity need flexibility within any guidelines. Exceptions will occur. Patients be evaluated...
Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify the presentation, characteristics, management, and clinical outcomes of irAEs.In this retrospective, observational case series, we reviewed medical records 1280 patients at a large US tertiary cancer center between 2010 2020.We identified 130 who presented irAEs...
We report the clinical outcomes of 22 patients with primary intraocular lymphoma (PIOL) treated over a 15-year period.Patients confirmed PIOL by central pathology review from 1994 to 2010 isolated ocular (N=13) or nervous system (CNS) plus involvement (N=9) were included. Intraocular and CNS failure-free survival, relapse-free overall survival analyzed.Median follow-up was 29.0 (range, 10.2 96.4) months. Sixteen (9 ocular, 7 disease) received combined modality therapy (CMT) consisting...
Purpose To evaluate a chemoreduction regimen using systemic vincristine and carboplatin (VC) local ophthalmic therapies to avoid external-beam radiotherapy (EBRT) or enucleation in patients with Group B intraocular retinoblastoma. Patients methods Twenty-one (25 eyes) were treated six cycles of VC, accompanied by after cycle 1. The primary study objective was determine the 2-year event-free survival (EFS) where an event defined as use chemotherapy addition carboplatin, EBRT, and/or...